MDB Capital (NASDAQ:MDBH) Trading Down 0.4% – Here’s Why

MDB Capital Holdings, LLC (NASDAQ:MDBH) shares dropped 0.4% during trading on Thursday . The company traded as low as $3.32 and last traded at $3.3850. 2,874 shares changed hands during mid-day trading, a decline of 30% from the average session volume of 4,122 shares. The stock had previously closed at $3.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDB Capital in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

MDB Capital Price Performance

The business’s fifty day simple moving average is $3.35 and its two-hundred day simple moving average is $3.31. The company has a market cap of $34.87 million, a PE ratio of -1.60 and a beta of 1.17.

MDB Capital (NASDAQ:MDBH) last posted its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter.

Institutional Trading of MDB Capital

Institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new stake in MDB Capital in the second quarter valued at approximately $27,000. DRW Securities LLC acquired a new position in shares of MDB Capital during the 4th quarter worth approximately $40,000. Finally, Citadel Advisors LLC acquired a new position in shares of MDB Capital during the 3rd quarter worth approximately $43,000. 0.35% of the stock is owned by institutional investors and hedge funds.

About MDB Capital

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.